Stock analysis, AI verdict, fundamentals & technical signals
Rating: SELL
Price: $128.62 Analyst target: $108.78 Upside: -15.43%
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.